Pfizer Receives All Regulatory Approvals to Complete Seagen Acquisition

Pfizer, close to completing the purchase of Seagen. The pharmaceutical company, which decided to acquire the biotechnology company that produces, develops and markets transformative anti-cancer products for $43 billion last March , has announced that it has received all the necessary regulatory approvals to complete its acquisition. Therefore, Pfizer expects to close the Seagen transaction on Thursday, December 14, subject to the satisfaction of other customary closing conditions.

To make this closure possible and address concerns from the US Federal Trade Commission, Pfizer has chosen to donate royalty rights from sales of Bavencio (avelumab) in the North American market to the American Association for Cancer Research ( Aacr). This unrestricted donation will support Ascr in its mission to prevent and cure cancer through research, education, communication, collaboration, science policy, and cancer research funding.

Along these same lines, the pharmaceutical company announces changes in its commercial organization to incorporate Seagen and improve the focus, speed and quality of execution. Pfizer will create an end-to-end commercial organization called Pfizer Oncology Division, which will integrate certain commercial and oncology research and development (R&D) operations of both companies.

Additionally, it will split its non-oncology business organization into two more focused business areas: the Pfizer U.S. Business Division and the Pfizer International Business Division.

Read more about the acquisition of Seagen by Pfizer and find the latest business news of the day with our companion app Born2Invest.

Pfizer expects Seagen to contribute $10 billion in revenue by 2030

Seagen expects to generate $2.2 billion (€2.063 billion) in revenue in 2023 , which will represent a 12% year-on-year increase for the biotechnology company. Pfizer expects Seagen to contribute more than $10 billion in revenue by 2030. The American company is a pioneer in the use of ADC technology, a tool that is emerging against different types of cancer to kill cancer cells and limit off-target toxicities.

Currently, the pharmaceutical company has a portfolio of 24 anti-cancer drugs that will generate more than $12 billion (€11 billion) in 2022, including best-selling therapies for metastatic breast cancer and prostate cancer. Pfizer focuses on four types of breast, prostate, genitourinary and precision medicine cancers. The proposed combination with Seagen would double Pfizer’s early-stage oncology clinical portfolio.

__

(Featured image by TBIT via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.